3/7/18 – 9/6/20

NCI, HHSN261201500036I; Task Order HHSN26100007 (PI: Grubbs)
Evaluation of STAT3 antagonist in the prevention of mammary cancer.
The objective of this task order is to test the efficacy of three new compounds for prevention of mammary cancers in rodent models of ER+ and ER- breast cancer.

7/15/18 – 1/14/21

NCI, HHSN26120150036I; Task Order HHSN26100008 (PI: Grubbs)
Prevention of urinary bladder cancer when two “clinically ready” agents (everolimus and naproxen) are administered in combination.
The objective of this task order is to evaluate the efficacy of everolimus and naproxen in combination in the prevention of urinary bladder cancer.

7/15/18 – 1/14/21

NCI, HHSN261201500036I; Task Order HHSN26100009 (PI: Grubbs)
Evaluating whether a concurrent retinoid x receptor agonist can enhance the efficacy of the HER-2-IGFPB2-IGFLR vaccine in eliminating existing ductal carcinoma in situ and preventing progression of invasive breast cancer.
The objective of this task order is to combine UAB-30 with a vaccine as a prevention against breast cancer.

9/17/18 – 9/16/19

NCI, HHSN26120150036I; Task Order HHSN26100010 (PI: Grubbs) 
Preclinical development of a chemopreventive agent 4-methylumbelliferone (4-MU).
The objective of this task order is to establish PK and PD assays for 4-MU and MUM in male and female Fischer—344 rats for future urinary bladder prevention studies.

9/17/18 – 3/16/20

NCI, HHSN26120150036I; Task Order HHSN26100011 (PI: Grubbs) 
Further development of multi-antigen vaccine for the primary and secondary prevention of bladder cancer.
The objective of this task order is to evaluate the prevention efficacy of the multi-antigen vaccine composed of Th1-biased epitopes from highly-expressed non-mutated antigens.

9/20/16 – 9/19/19

NCI, HHSN261201500036I, Task Order # HHSN26100004 (PI: Grubbs) 
Immunologic effects of NSAIDs with and without a vaccine in colon cancer prevention.
The objective of this project is to treat the efficacy of NSAIDs alone and in combination with an antigen-specific vaccine as chemopreventive agents for colorectal cancer.

6/19/17 – 9/18/19

NCI, HHSN261201500036I; Task Order # HHSN26100005 (PI: Grubbs)
Evaluation of “Clinical Ready” agents (Bazedoxifene and Lapatinib) in combination for the prevention of ER+ and ER- mammary cancers.
The objective of this task order is to test the efficacy of the two FDA-approved drugs at low doses and either alone or in combination for prevention of cancers in rodent models of ER+ and ER- breast cancer.

9/15/17 – 9/14/19

NCI, HHSN261201500036I; Task Order # HHSN2610000 (PI: Grubbs) 
Multi-antigen vaccines for the primary and secondary prevention of bladder cancer.
The objective of this task order is to evaluate the efficacy of a vaccine composed of Th1-selective epitopes from non-mutated self-antigens to prevent chemically-induced urinary bladder cancer.

3/1/16 – 8/31/19

NCI, 1R21CA195394; (PI: Tatjana Coric; Co-investigator: Grubbs)
Chemoprevention of breast Cancer and secondary prevention of bladder cancer.
The objective of this task grant is to determine of the chemopreventive retinoid UAB126 will prevent metabolic syndrome and lipogenesis induced by high-fat diet.

3/1/16 – 9/28/19

Breast Cancer Research Foundation of Alabama (PI: Grubbs) 
Retinoids for the prevention of breast cancer.
The objective of this proposal is to determine if Class III will be active in the prevention of ER- mammary cancer is in obese mice.

9/1/17 – 8/31/22

NCI, 1P) 1CA210946-01 (PI: Elmets; Co-investigator: Grubbs)
RXR retinoids for cancer chemoprevention.
The primary objective is to access the efficacy of oral administration of UAB30 at inhibiting expression of cyclin D1 in actinically damaged skin.

1/1/18 – 12/31/19

Breast Cancer Research Foundation of Alabama; (Co-PIs: Piazza, Grubbs) 
Evaluation of a novel sulindac derivative for breast cancer chemoprevention in a rat model of chemically-induced mammary tumorigenesis.
The objective is to determine the efficacy and toxicity of a novel PDE 10/β-caterin inhibitor in the MNU-induced mammary cancer model.